Search

News Assessment of the Effectiveness of Superabsorbent Dressings from the Perspective of Doctors and Patients

The Journal of Wound Care published the results of an observational study on the benefits of Resposorb Super superabsorbent dressings in the treatment of acute and chronic wounds with higher levels of exudate.

Source: Wound Healing 5. 10. 2022

News Can SGLT2 Inhibition Also Reduce the Risk of Nephrolithiasis?

Diabetes mellitus (DM) is a risk factor for the development of nephrolithiasis. Recent studies associated with nephrolithiasis suggest a possible beneficial effect of sodium-glucose cotransporter 2 inhibitors (SGLT2i, also known as gliflozins), a significant group of modern antidiabetics. Below we summarize findings from a study that explored this potential in empagliflozin using conducted phase I–IV studies, including EMPA-REG OUTCOME.

Source: Diabetes 21. 8. 2023

Články časopisu Relation of the Severity of Atopic Dermatitis and Occurrence of Respiratory Allergy to Dust, Animal Dander, Mites, Feather and IgE Food Allergy to Cow´s Milk, Egg, Soy, Peanuts and Wheat

Author of the article: J. Čelakovská Source: Česko-slovenská dermatologie | 6/2016 15. 12. 2016

News Liposomal Pegylated Irinotecan in the Treatment of Pancreatic Tumors

Combined treatment with liposomal pegylated irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) significantly improves overall survival in patients with metastatic ductal carcinoma of the pancreas. Analysis of the NAPOLI clinical trial revealed prognostic markers for long-term survival in patients treated this way.

Source: Treatment of Gastrointestinal Carcinomas 11. 5. 2021

News What Did 3 Years of Data from the Czech National COPD Database Reveal?

In December of last year, the Czech multicenter research database on COPD was completed. This was an extensive 5-year project in which researchers included 784 patients with significant chronic obstructive pulmonary disease (FEV₁ ≤ 60%) from 14 centers. This represents approximately 1% of the total number of patients with this diagnosis in the Czech Republic, making the study sample fairly representative for obtaining data on treatment in Czech real practice. Three-year data are currently available. What have they shown so far? This was summarized during this year's Hradec Pulmonology Days by Dr. Jaromír Zatloukal, Ph.D., from the Clinic of Pulmonary Diseases and TB at the Faculty of Medicine, Palacký University and University Hospital Olomouc.

Source: Cough Therapy 24. 5. 2022

News Effectiveness of Compression Therapy in Patients with Leg Ulcers

Up to 2% of the population suffers from leg ulcers. The standard treatment for ulcers of venous etiology is compression. The following French study, whose results were recently published in the International Journal of Angiology, examined its effectiveness and safety in patients with mixed (arteriovenous) etiology ulcers.

Source: Wound Healing 8. 11. 2022

News Compression therapy in combination with surgical intervention in the treatment of venous leg ulcers and prevention of their recurrence

Compression therapy represents an important part of the treatment of venous leg ulcers; it also plays a role in preventing possible recurrences. The 4-year British ESCHAR study evaluated the impact of combining compression therapy with surgical correction of reflux in the superficial venous system on the healing and potential recurrence of venous leg ulcers compared to compression therapy alone.

Source: Wound Healing 12. 6. 2023

News Expert Consensus on the Use of Bimekizumab in the Treatment of Plaque Psoriasis and Psoriatic Arthritis

The expert consensus published in February 2024 offers guidance on the use of bimekizumab in the treatment of patients with moderate to severe plaque psoriasis and psoriatic arthritis. It is based on a literature review and an assessment of data from 19 relevant studies. A panel of 9 American dermatologists specializing in psoriasis treatment created and adopted 14 consensus statements and recommendations, 12 of which have a strength of “A”.

Source: Psoriasis 16. 5. 2024

News Long-term effect of the triple combination of perindopril, indapamide, and amlodipine on left ventricular hypertrophy in hypertension

A recent open-label interventional study aimed to describe the long-term effect of a fixed triple combination of perindopril, indapamide, and amlodipine compared to a free combination of a RAAS inhibitor, diuretic, and calcium channel blocker on the reduction of left ventricular hypertrophy (LVH) in hypertensive outpatients.

Source: ACE inhibitory 18. 4. 2021

News What is the Impact of Bisoprolol on Plasma Concentrations of Dabigatran

Many patients on anticoagulant therapy with dabigatran also use the beta-blocker bisoprolol. The Slovak prospective observational study was based on the assumption that bisoprolol, as a significant inhibitor of P-glycoprotein, may interact with dabigatran and focused on examining the effect of this beta-blocker on plasma concentrations of dabigatran.

Source: Cardiovascular Continuum 16. 9. 2022

News Targeted Treatment of Children and Adolescents with Severe AD –⁠ Case Studies

The results of therapy with dupilumab in children and adolescents with severe forms of atopic dermatitis (AD) are very good even after a short period, not only from a health perspective but also in terms of the social aspect of the disease and the quality of life of patients. This is illustrated by the following two case studies –⁠ an 8-year-old girl and a 17-year-old boy –⁠ from the Center for Biological Treatment at the Dermatovenerology Clinic of the 2nd Faculty of Medicine, Charles University, and Bulovka University Hospital.

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 2. 3. 2023

News Dual Inhibition of IL-17A/IL-17F Across the Spectrum of Axial Spondyloarthritis

Many patients with axial spondyloarthritis (axSpA) still have a need to seek additional therapeutic options and new mechanisms of action for medicinal substances. Phase III studies BE MOBILE 1 and 2 therefore evaluated the effect of administering bimekizumab—a monoclonal antibody selectively inhibiting interleukins (IL) 17A and 17F—across the full spectrum of patients with axSpA.

Source: Rheumatic Diseases 1. 12. 2023

News Safety and Efficacy of Long-term Tofacitinib Therapy in Patients with Active Psoriatic Arthritis –⁠ Interim Results of the OPAL Balance Study

Tofacitinib is a potent selective inhibitor of the Janus kinase (JAK) family indicated for the treatment of active psoriatic arthritis in adult patients. The efficacy and safety of tofacitinib in this population have been verified for 6 and 12 months through clinical studies OPAL. A study published in 2020 presents interim results of the extended phase of these studies, evaluating its efficacy and safety in the long term.

Source: Arthritis 30. 5. 2022

News Improvement of Joint and Skin Symptoms and Their Contribution to Improving the Quality of Life in Patients with Psoriatic Arthritis

The cause of reduced quality of life in patients with psoriatic arthritis is the involvement of both skin and joints. Commonly used therapy certainly improves symptoms of both systems to some extent, but to what extent does this improvement correlate with a higher health-related quality of life? This question was addressed by analyzing two randomized studies.

Source: Biological Treatment 21. 8. 2020

News Venetoclax in the Treatment of CLL: Open Doors for the Longest Possible Maintenance of Remission Without Active Therapy

William G. Wierda from MD Anderson Cancer Center in Houston, USA, and Francesco P. Tambaro from Azienda Ospedaliera di Rilievo Nazionale Santobono-Pausilipon in Naples, Italy, evaluate in their report for the journal Blood from April 2020 the practical aspects and benefits of using venetoclax in the first-line treatment of chronic lymphocytic leukemia (CLL), as well as in cases of relapsing/refractory forms of the disease.

Source: Chronic Lymphocytic Leukemia 8. 6. 2020